NCT04397276View on ClinicalTrials.gov

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

July 10, 2020

Primary Completion Date

September 30, 2025

Study Completion Date

October 30, 2025

Conditions
Neoplasms
Interventions
DRUG

JNJ-70218902

JNJ-70218902 will be administered.

Trial Locations (7)

28040

Hosp Univ Fund Jimenez Diaz, Madrid

28050

Hosp Univ Hm Sanchinarro, Madrid

31096

Rambam Medical Center, Haifa

64239

Sourasky Medical Center, Tel Aviv

V5Z 4E6

BC Cancer Agency - Vancouver BC, Vancouver

M5G 2M9

Princess Margaret Hospital, Toronto

08035

Hosp Univ Vall D Hebron, Barcelona

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY